Brolucizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB14864 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 34 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 2 | esophageal varices without bleeding | KG + DL |
| 3 | esophageal varices with bleeding | KG + DL |
| 4 | exocrine pancreatic insufficiency | KG + DL |
| 5 | MRCS syndrome | KG + DL |
| 6 | pigmented paravenous retinochoroidal atrophy | KG + DL |
| 7 | familial flecked retinopathy | KG + DL |
| 8 | ectopia lentis-chorioretinal dystrophy-myopia syndrome | KG + DL |
| 9 | retinal dystrophy in systemic or cerebroretinal lipidoses | KG + DL |
| 10 | senile reticular retinal degeneration | KG + DL |
| 11 | Blessig’s cysts | KG + DL |
| 12 | pseudoretinitis pigmentosa | KG + DL |
| 13 | cone dystrophy | KG + DL |
| 14 | genetic macular dystrophy | KG + DL |
| 15 | X-linked retinal dysplasia | KG + DL |
| 16 | progressive bifocal chorioretinal atrophy | KG + DL |
| 17 | varicose disease | KG + DL |
| 18 | retinal drusen | KG + DL |
| 19 | retinoschisis | KG + DL |
| 20 | helicoid peripapillary chorioretinal degeneration | KG + DL |
| 21 | retinoschisis of fovea | KG + DL |
| 22 | familial benign flecked retina | KG + DL |
| 23 | oligocone trichromacy | KG + DL |
| 24 | Aland island eye disease | KG + DL |
| 25 | immunodeficiency with factor H anomaly | KG + DL |
| 26 | late-onset retinal degeneration | KG + DL |
| 27 | preretinal fibrosis | KG + DL |
| 28 | hole retinal cyst | KG + DL |
| 29 | cystoid macular retinal degeneration | KG + DL |
| 30 | toxic maculopathy | KG + DL |
| 31 | hemolytic uremic syndrome, atypical, susceptibility to, 1 | KG + DL |
| 32 | Bothnia retinal dystrophy | KG + DL |
| 33 | macular dystrophy with central cone involvement | KG + DL |
| 34 | retinitis punctata albescens | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.